PMID- 36292014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 12
IP  - 10
DP  - 2022 Sep 26
TI  - Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor 
      Responders at Interim Assessment.
LID - 10.3390/diagnostics12102325 [doi]
LID - 2325
AB  - (1) This study aimed to investigate whether baseline clinical and Positron 
      Emission Tomography/Computed Tomography (bPET)-derived parameters could help 
      predicting early response to the first two cycles of chemotherapy (Deauville 
      Score at interim PET, DS at iPET) in patients with classical Hodgkin lymphoma 
      (cHL) to identify poor responders (DS >/= 4) who could benefit from first-line 
      treatment intensification at an earlier time point. (2) cHL patients with a bPET 
      and an iPET imaging study in our Centre's records (2013-2019), no 
      synchronous/metachronous tumors, no major surgical resection of disease prior to 
      bPET, and treated with two cycles of ABVD chemotherapy before iPET were 
      retrospectively included. Baseline International Prognostic Score for HL (IPS) 
      parameters were collected. Each patient's bPET total metabolic tumor volume 
      (TMTV) and highest tumoral SUVmax were collected. ROC curves and Youden's index 
      were used to derive the optimal thresholds of TMTV and SUVmax with regard to the 
      DS (>/=4). Chi-square or Fisher's exact test were used for the univariate analysis. 
      A multivariate analysis was then performed using logistic regression. The type I 
      error rate in the hypothesis testing was set to 5%. (3) A total of 146 patients 
      were included. The optimal threshold to predict a DS >/= 4 was >177 mL for TMTV and 
      >14.7 for SUVmax (AUC of 0.65 and 0.58, respectively). The univariate analysis 
      showed that only TMTV, SUVmax, advanced disease stage, and age were significantly 
      associated with a DS >/= 4. A multivariate model was finally derived from TMTV, 
      SUVmax, and age, with an AUC of 0.77. (4) A multivariate model with bPET 
      parameters and age at diagnosis was satisfactorily predictive of poor response at 
      iPET after ABVD induction chemotherapy in cHL patients. More studies are needed 
      to validate these results and further implement DS-predictive factors at baseline 
      in order to prevent poor response and intensify therapeutic strategies a-priori 
      when needed.
FAU - Triumbari, Elizabeth Katherine Anna
AU  - Triumbari EKA
AUID- ORCID: 0000-0001-6932-2276
AD  - Nuclear Medicine Unit, TracerGLab, Department of Radiology, Radiotherapy and 
      Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, 
      Italy.
FAU - Morland, David
AU  - Morland D
AUID- ORCID: 0000-0001-8738-4841
AD  - Nuclear Medicine Unit, TracerGLab, Department of Radiology, Radiotherapy and 
      Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, 
      Italy.
AD  - Service de Medecine Nucleaire, Institut Godinot, 51100 Reims, France.
AD  - Laboratoire de Biophysique, UFR de Medecine, Universite de Reims 
      Champagne-Ardenne, 51100 Reims, France.
AD  - CReSTIC (Centre de Recherche en Sciences et Technologies de l'Information et de 
      la Communication), EA 3804, Universite de Reims Champagne-Ardenne, 51100 Reims, 
      France.
FAU - Cuccaro, Annarosa
AU  - Cuccaro A
AUID- ORCID: 0000-0002-0237-1839
AD  - Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione 
      Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
AD  - Hematology Unit, Center for Translational Medicine, Azienda USL Toscana 
      NordOvest, 55100 Livorno, Italy.
FAU - Maiolo, Elena
AU  - Maiolo E
AUID- ORCID: 0000-0001-8956-7502
AD  - Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione 
      Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
FAU - Hohaus, Stefan
AU  - Hohaus S
AUID- ORCID: 0000-0002-5534-7197
AD  - Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione 
      Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
AD  - Hematology Section, Department of Radiological Sciences and Hematology, 
      Universita Cattolica del Sacro Cuore, 00168 Rome, Italy.
FAU - Annunziata, Salvatore
AU  - Annunziata S
AD  - Nuclear Medicine Unit, TracerGLab, Department of Radiology, Radiotherapy and 
      Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, 
      Italy.
LA  - eng
GR  - GR-2019-12370372/Italian Ministry of Health/
PT  - Journal Article
DEP - 20220926
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC9600607
OTO - NOTNLM
OT  - 18F-FDG PET/CT
OT  - Deauville Score
OT  - SUVmax
OT  - classical Hodgkin lymphoma
OT  - early response assessment
OT  - total metabolic tumor volume
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/09/26
CRDT- 2022/10/27 01:15
PHST- 2022/06/20 00:00 [received]
PHST- 2022/08/24 00:00 [revised]
PHST- 2022/09/22 00:00 [accepted]
PHST- 2022/10/27 01:15 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/09/26 00:00 [pmc-release]
AID - diagnostics12102325 [pii]
AID - diagnostics-12-02325 [pii]
AID - 10.3390/diagnostics12102325 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2022 Sep 26;12(10):2325. doi: 10.3390/diagnostics12102325.